Proof-of-concept phase I trial of ACH 3422 in patients with chronic hepatitis C
Phase of Trial: Phase I
Latest Information Update: 05 Mar 2015
Price : $35 *
At a glance
- Drugs ACH 3422 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Proof of concept
- 05 Mar 2015 Results are anticipated during the second quarter of 2015, according to an Achillion Pharmaceuticals media release.
- 05 Mar 2015 Planned initiation date changed from 1 Jul 2014 to 1 Mar 2015, according to an Achillion Pharmaceuticals media release.
- 14 Feb 2014 New trial record